Quarterly report pursuant to Section 13 or 15(d)

Stock Based Compensation (Details)

v3.19.2
Stock Based Compensation (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 01, 2019
$ / shares
shares
May 18, 2016
grant
shares
Apr. 05, 2016
USD ($)
shares
Apr. 30, 2019
shares
Aug. 31, 2018
USD ($)
May 31, 2018
shares
Jun. 30, 2019
USD ($)
day
$ / shares
shares
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
Dec. 31, 2018
$ / shares
shares
Annual share reserve increase (as a percent)                 4.00%    
Total stock-based compensation | $             $ 526,709 $ 608,431 $ 1,123,402 $ 851,255  
Research and development                      
Total stock-based compensation | $             120,709 20,379 178,085 31,876  
General and administrative                      
Total stock-based compensation | $             196,211 549,199 665,336 756,581  
Sales and marketing                      
Total stock-based compensation | $             209,789 $ 38,853 279,981 62,798  
Service Based Options                      
Total stock-based compensation | $             $ 600,000   $ 900,000    
Option Activity, Number of shares                      
Balance, beginning of period (in shares) 3,746,597               3,746,597    
Granted (in shares)                 2,381,627    
Options exercises in period (in shares)                 (74,902)    
Forfeitures (in shares)                 (796,063)    
Expired (in shares)                 (80,712)    
Balance, end of period (in shares)             5,176,547   5,176,547   3,746,597
Exercisable (in shares)             2,321,047   2,321,047    
Option Activity, Weighted-average exercise price                      
Beginning of period (in dollars per share) | $ / shares $ 4.16               $ 4.16    
Granted (in dollars per share) | $ / shares                 5.96    
Exercised (in dollars per share) | $ / shares                 3.44    
Forfeitures (in dollars per share) | $ / shares                 5.12    
Expired (in dollars per share) | $ / shares                 7.95    
End of period (in dollars per share) | $ / shares             $ 4.79   4.79   $ 4.16
Exercisable (in dollars per share) | $ / shares             $ 4.38   $ 4.38    
Option Activity, Fair value of options granted                      
Grant date fair value of options granted | $             $ 7,691,720   $ 7,691,720    
Grant date fair value of options forfeited | $             2,325,463   2,325,463    
Weighted average grant date fair value of options expired | $             279,812   $ 279,812    
Option Activity, Weighted-average remaining contractual term (in years)                      
Balance                 8 years 3 months 18 days   7 years 9 months 18 days
Exercisable                 7 years    
Aggregate intrinsic value | $             6,300,000   $ 6,300,000    
Exercisable aggregate intrinsic value | $             $ 4,300,000   4,300,000    
Intrinsic value of options exercised | $                 100,000    
Fair value of options vested in period | $                 $ 1,000,000    
Per share weighted average fair value of options granted (in dollars per share) | $ / shares                 $ 3.23    
Options vested (in shares)                 480,680    
Weighted average exercise price (in dollars per share) | $ / shares             $ 3.49   $ 3.49    
Compensation not yet recognized | $             $ 7,500,000   $ 7,500,000    
Period for recognition                 3 years 3 months 18 days    
Fair value assumptions                      
Expected annual dividend yield                 0.00%    
Expected volatility rate, minimum                 55.00%    
Expected volatility rate, maximum                 65.00%    
Stock Options With Market Based Vesting Conditions                      
Total stock-based compensation | $             $ (400,000)     $ (300,000)  
Option Activity, Number of shares                      
Balance, beginning of period (in shares) 500,000               500,000    
Granted (in shares)                 300,000    
Options exercises in period (in shares)                 0    
Forfeitures (in shares)                 (500,000)    
Balance, end of period (in shares)             300,000   300,000   500,000
Exercisable (in shares)             0   0    
Option Activity, Weighted-average exercise price                      
Beginning of period (in dollars per share) | $ / shares $ 4.24               $ 4.24    
Granted (in dollars per share) | $ / shares                 4.98    
Forfeitures (in dollars per share) | $ / shares                 4.24    
End of period (in dollars per share) | $ / shares             $ 4.98   $ 4.98   $ 4.24
Option Activity, Weighted-average remaining contractual term (in years)                      
Balance                 9 years 10 months 24 days   9 years 2 months 27 days
Aggregate intrinsic value | $             $ 138,000   $ 138,000    
Compensation not yet recognized | $             1,000,000   $ 1,000,000    
Period for recognition                 2 years 6 months    
Fair value assumptions                      
Expected annual dividend yield                 0.00%    
Expected volatility                 60.00%    
Expected term of options (in years)                 10 years    
Risk-free interest rate                 2.32%    
Restricted Stock Awards                      
Award vesting period                 4 years    
Total stock-based compensation | $             300,000   $ 400,000    
Compensation not yet recognized | $             $ 1,400,000   $ 1,400,000    
Option Activity, Weighted-average remaining contractual term (in years)                      
Period for recognition                 2 years 9 months 18 days    
Non-vested RSUs Outstanding                      
RSAs granted (in shares)                 295,000    
RSAs vested (in shares)                 161,250    
RSAs forfeited (in shares)                 (300,000)    
Ending balance of Non-vested RSAs (in shares)             278,750   278,750   445,000
Weighted average grant date fair value                      
Nonvested RSAs weighted average grant date fair value (in dollars per share) | $ / shares                     $ 4.27
Nonvested RSAs grants in period weighted average grant date fair value (in dollars per share) | $ / shares                 $ 4.98    
RSAs vested in period weighted average grant date fair value (in dollars per share) | $ / shares                 4.49    
Nonvested RSAs forfeitures weighted average grant date fair value (in dollars per share) | $ / shares                 $ 4.24    
Employee Stock Purchase Plan (ESPP)                      
Total stock-based compensation | $             $ 52,388   $ 87,685    
Minimum | Service Based Options                      
Fair value assumptions                      
Expected term of options (in years)                 5 years    
Risk-free interest rate                 1.76%    
Maximum | Service Based Options                      
Fair value assumptions                      
Expected term of options (in years)                 6 years 3 months    
Risk-free interest rate                 2.59%    
2016 Plan                      
Increase in number of shares reserved for issuance (in shares)   600,000       1,400,000.0          
Common stock remaining for future issuance (in shares)             934,972   934,972    
2016 Plan | Equity Option                      
Award expiration period                 10 years    
2015 Plan                      
Number of grants to be made | grant   0                  
Common stock remaining for future issuance (in shares)   464,476                  
2011 Stock Incentive Plan                      
Number of grants to be made | grant   0                  
Employee Stock Purchase Plan (ESPP)                      
Common stock remaining for future issuance (in shares)             1,148,085   1,148,085    
Weighted average grant date fair value                      
Percentage of fair market value on the lower of first day or last day of the offering period at which employees may purchase stock under the ESPP     85.00%                
Maximum portion of earning an employee may contribute to the ESPP Plan     15.00%                
Maximum annual amount of fair market value of the Company's common stock that a participant may accrue the rights to purchase | $     $ 25,000                
Shares of common stock for future issuance (in shares)     500,000                
Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year     1.00%                
Increase in shares available (in shares) 408,042                    
Employee | 2016 Plan | Minimum | Equity Option                      
Award vesting period                 3 years    
Employee | 2016 Plan | Maximum | Equity Option                      
Award vesting period                 4 years    
Director | 2016 Plan | Equity Option                      
Award vesting period                 3 years    
Terminated Executive                      
Total stock-based compensation | $                 $ 300,000    
Terminated Executive | Option And Non Option Awards                      
Forfeitures (in shares)       1,489,583              
Terminated Executive | Service Based Options                      
Option Activity, Number of shares                      
Forfeitures (in shares)       (689,583)              
Terminated Executive | Stock Options With Market Based Vesting Conditions                      
Option Activity, Number of shares                      
Forfeitures (in shares)       (500,000)              
Terminated Executive | Restricted Stock Awards                      
Total stock-based compensation | $             $ (500,000)        
Requisite service period       2 years 9 months 18 days              
Non-vested RSUs Outstanding                      
RSAs forfeited (in shares)       (300,000)              
Board of Directors Chairman | Stock Options With Market Based Vesting Conditions                      
Option Activity, Number of shares                      
Granted (in shares)             300,000        
Option Activity, Weighted-average exercise price                      
Granted (in dollars per share) | $ / shares             $ 4.98        
Board of Directors Chairman | Restricted Stock Awards                      
Non-vested RSUs Outstanding                      
RSAs granted (in shares)             250,000        
RSAs vested (in shares)             50,000        
Tranche One | Board of Directors Chairman | Stock Options With Market Based Vesting Conditions                      
Award vesting percentage             33.33%        
Weighted average grant date fair value                      
Number of days above threshold to trigger vesting | day             3        
Tranche One | Board of Directors Chairman | Restricted Stock Awards                      
Award vesting percentage                 33.33%    
Tranche One | Board of Directors Chairman | Minimum                      
Share Price | $ / shares             $ 8.00   $ 8.00    
Tranche Two | Board of Directors Chairman | Stock Options With Market Based Vesting Conditions                      
Award vesting percentage             33.33%        
Weighted average grant date fair value                      
Number of days above threshold to trigger vesting | day             3        
Tranche Two | Board of Directors Chairman | Restricted Stock Awards                      
Award vesting percentage                 33.33%    
Tranche Two | Board of Directors Chairman | Minimum                      
Share Price | $ / shares             $ 10.50   $ 10.50    
Tranche Three | Board of Directors Chairman | Stock Options With Market Based Vesting Conditions                      
Award vesting percentage             33.33%        
Weighted average grant date fair value                      
Number of days above threshold to trigger vesting | day             3        
Tranche Three | Board of Directors Chairman | Restricted Stock Awards                      
Award vesting percentage                 33.33%    
Tranche Three | Board of Directors Chairman | Minimum                      
Share Price | $ / shares             $ 13.00   $ 13.00    
Karbinal Agreement | TRIS Pharma                      
Make whole payment | $         $ 900,000   $ 400,000   $ 800,000